Related Experiment Video

Updated: Jan 16, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.3K

Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance

Fei Du1, Lu Tang2, Fang Wang3,4

  • 1Department of Pharmacy, The Fourth Affiliated Hospital Of Southwest Medical University, 620000, Meishan, Sichuan, PR China.

Molecular Cancer
|September 26, 2025
PubMed

Insights

Cuproptosis, a programmed cell death pathway, shows promise against tumor drug resistance by targeting mitochondria. Non-coding RNAs (ncRNAs) epigenetically regulate cuproptosis, offering new therapeutic strategies for overcoming treatment failure.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Tumor drug resistance is a major obstacle in cancer therapy, leading to treatment failure and relapse.
  • Cuproptosis, a novel form of programmed cell death, targets mitochondrial metabolism and presents a potential strategy against drug resistance.
  • Mitochondrial-targeted therapies face challenges due to essential roles in normal tissues, necessitating precise regulatory mechanisms.

Purpose of the Study:

  • To review the mechanisms of cuproptosis and its role in overcoming cancer drug resistance.
  • To explore the epigenetic regulation of cuproptosis by non-coding RNAs (ncRNAs).
  • To highlight the ncRNA-cuproptosis interaction network's significance in therapeutic response and cancer progression.

Main Methods:

  • Literature review summarizing current research on cuproptosis, drug resistance, and ncRNAs.
  • Analysis of molecular mechanisms linking cuproptosis, epigenetic modifications, and therapeutic outcomes.
  • Synthesis of findings on ncRNA-mediated regulation of cuproptosis in various cancer therapies.

Main Results:

  • Cuproptosis offers a novel approach to combatting drug resistance by targeting cancer cell metabolism.
  • Epigenetic alterations mediated by ncRNAs dynamically influence susceptibility to cuproptosis.
  • ncRNAs play a critical role in modulating resistance to chemotherapy, immunotherapy, and targeted therapy through cuproptosis.

Conclusions:

  • The ncRNA-cuproptosis axis is a key regulator of tumor drug resistance.
  • Targeting ncRNAs and cuproptosis presents a promising therapeutic avenue for overcoming treatment resistance.
  • Understanding ncRNA-epigenetic modulation of cuproptosis is crucial for developing effective cancer treatments.
Keywords:
CancerCuproptosisDrug resistanceEpigenetic modificationNon-coding RNAs

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.7K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K